Xichen Lin Buys Shares of Structure Therapeutics Inc.
Xichen Lin, Chief Scientific Officer, acquired 7,878 shares of Structure Therapeutics Inc. on June 25, 2026.
Key Points
- Xichen Lin, Chief Scientific Officer at Structure Therapeutics, bought 7,878 shares on June 25, 2026.
- Structure Therapeutics Inc. trades on NasdaqGM under the ticker GPCR, with a market cap of $3.53 billion.
- Analysts maintain a strong buy rating for GPCR, with a mean target price of $104.59.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Xichen Lin, the Chief Scientific Officer at Structure Therapeutics Inc. (NasdaqGM: GPCR), purchased 7,878 shares of the company on June 25, 2026. This insider transaction did not involve a planned purchase and the shares were acquired at no cost, as part of a compensation-related transaction.
Insider Buying and Selling at Structure Therapeutics Inc.
On June 25, 2026, Xichen Lin, who serves as the Chief Scientific Officer, acquired 7,878 shares of Structure Therapeutics Inc. This transaction was not part of a pre-arranged trading plan. Additionally, Daniel Welch made a purchase of 39,453 shares on June 17, 2026.
Structure Therapeutics Inc. Stock Up 9.1%
Shares of NasdaqGM:GPCR traded near $51.69 on Tuesday. Structure Therapeutics Inc. has a market capitalization of approximately $3.53 billion. The company's forward P/E ratio is not meaningful as it is not profitable, and the stock has a beta of -1.423. Over the past year, the stock has ranged from a low of $15.80 to a high of $94.90. Its 50-day moving average is $42.06, and its 200-day moving average is $48.88. The company maintains a strong liquidity position with a current ratio of 26.16 and a quick ratio of 25.60.
$GPCR stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 11, 2026, HC Wainwright & Co. maintained a buy rating for Structure Therapeutics Inc. with a price target of $70.00. Earlier, on April 27, 2026, Canaccord Genuity initiated coverage with a buy rating and a $101.00 price target. The consensus among analysts is a strong buy recommendation, with an average target price of $104.59 based on 16 opinions.
About Structure Therapeutics Inc.
Structure Therapeutics Inc. is a biotechnology company based in South San Francisco, California. It focuses on developing oral small molecule therapeutics to address chronic diseases with unmet medical needs. The company's leading candidate, GSBR-1290, targets obesity and related conditions and is in phase 2 trials. Structure Therapeutics also works on other compounds for obesity, pulmonary fibrosis, and metabolic diseases under the leadership of CEO Dr. Raymond C. Stevens. The company employs 233 people.
Bottom Line
Xichen Lin's recent purchase of shares in Structure Therapeutics Inc. highlights ongoing insider activity within the company. As a clinical-stage biopharmaceutical firm, Structure Therapeutics is closely watched for its innovative solutions in the healthcare sector. Investors often track insider transactions like Lin's for potential insights, though it's important to remember that such filings reflect past actions and may not indicate current positions.
Get Structure Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $GPCR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.